Trial Condition(s):

Renal anemia

BAY85-3934, Liver impairment study

Bayer Identifier:

14634

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2013-003944-22

Study Completed

Trial Purpose

The study was conducted in a single-center, non-randomized, non-controlled, nonblinded, observational design with group stratification.

Inclusion Criteria
- Male and female white subjects aged between 18 to 79 years with a body mass index (BMI) of 18 to 34 kg/m2;
- Subjects with hepatic impairment Child Pugh A or B with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan;
- Age, weight and gender matched healthy subjects (mean age and body weight in the control group and in the 2 groups with hepatic impairment were not to vary by more than ± 10 years and ± 10 kg).
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
27
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Musredo (Molidustat, BAY85-3934)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Kiel, Germany, 24105

Status
Completed
 

For details, please refer to trial results

Additional Information